Cargando…

Increased AGE-RAGE ratio in idiopathic pulmonary fibrosis

BACKGROUND: The abnormal epithelial-mesenchymal restorative capacity in idiopathic pulmonary fibrosis (IPF) has been recently associated with an accelerated aging process as a key point for the altered wound healing. The advanced glycation end-products (AGEs) are the consequence of non-enzymatic rea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Machahua, Carlos, Montes-Worboys, Ana, Llatjos, Roger, Escobar, Ignacio, Dorca, Jordi, Molina-Molina, Maria, Vicens-Zygmunt, Vanesa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5097848/ https://www.ncbi.nlm.nih.gov/pubmed/27816054 http://dx.doi.org/10.1186/s12931-016-0460-2

Ejemplares similares

Serum AGE/RAGEs as potential biomarker in idiopathic pulmonary fibrosis
por: Machahua, Carlos, et al.
Publicado: (2018)

Fibroblast viability and phenotypic changes within glycated stiffened three-dimensional collagen matrices
por: Vicens-Zygmunt, Vanesa, et al.
Publicado: (2015)

Erratum to: Fibroblast viability and phenotypic changes within glycated stiffened three-dimensional collagen matrices
por: Vicens-Zygmunt, Vanesa, et al.
Publicado: (2015)

Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells
por: Molina-Molina, M., et al.
Publicado: (2018)

Lung fibrotic tenascin-C upregulation is associated with other extracellular matrix proteins and induced by TGFβ1
por: Estany, Susanna, et al.
Publicado: (2014)

Identification of MMP28 as a biomarker for the differential diagnosis of idiopathic pulmonary fibrosis
por: Maldonado, Mariel, et al.
Publicado: (2018)

Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis: a cross-sectional study in two independent cohorts
por: Machahua, Carlos, et al.
Publicado: (2021)

Experience With Nintedanib in Severe Pulmonary Fibrosis Associated With Systemic Sclerosis: A Case Series
por: Bordas-Martinez, Jaume, et al.
Publicado: (2021)

Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial
por: Molina-Molina, Maria, et al.
Publicado: (2023)

Predictors and changes of physical activity in idiopathic pulmonary fibrosis
por: Badenes-Bonet, Diana, et al.
Publicado: (2022)

Idiopathic pulmonary fibrosis cluster analysis highlights diagnostic delay and cardiovascular comorbidity association with outcome
por: Bordas-Martínez, Jaume, et al.
Publicado: (2021)

Lung Transplant Improves Survival and Quality of Life Regardless of Telomere Dysfunction
por: Planas-Cerezales, Lurdes, et al.
Publicado: (2021)

Systemic and Pulmonary Vascular Remodelling in Chronic Obstructive Pulmonary Disease
por: Muñoz-Esquerre, Mariana, et al.
Publicado: (2016)

Mitochondrial Dysfunction in Lung Resident Mesenchymal Stem Cells from Idiopathic Pulmonary Fibrosis Patients
por: Mercader-Barceló, Josep, et al.
Publicado: (2023)

Changes in serum metabolomics in idiopathic pulmonary fibrosis and effect of approved antifibrotic medication
por: Seeliger, Benjamin, et al.
Publicado: (2022)

The JAK2 pathway is activated in idiopathic pulmonary fibrosis
por: Milara, Javier, et al.
Publicado: (2018)

Clinical implications of ANCA positivity in idiopathic pulmonary fibrosis patients
por: Suarez-Cuartin, Guillermo, et al.
Publicado: (2020)

Telomere Shortening Is behind the Harm of Immunosuppressive Therapy in Idiopathic Pulmonary Fibrosis
por: Molina-Molina, Maria
Publicado: (2019)

Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World
por: Polke, Markus, et al.
Publicado: (2021)

Assessing quality of life of idiopathic pulmonary fibrosis patients: the INSTAGE study
por: Suarez-Cuartin, Guillermo, et al.
Publicado: (2019)

Idiopathic pulmonary fibrosis and the role of genetics in the era of precision medicine
por: Alonso-Gonzalez, Aitana, et al.
Publicado: (2023)

Multidisciplinary approach and long-term follow-up in a series of 640 consecutive patients with sarcoidosis: Cohort study of a 40-year clinical experience at a tertiary referral center in Barcelona, Spain
por: Mañá, Juan, et al.
Publicado: (2017)

The perplexing role of RAGE in pulmonary fibrosis: causality or casualty?
por: Perkins, Timothy N., et al.
Publicado: (2021)

Increased Expression of CC16 in Patients with Idiopathic Pulmonary Fibrosis
por: Buendía-Roldán, Ivette, et al.
Publicado: (2016)

Reduced endogenous secretory RAGE in blood and bronchoalveolar lavage fluid is associated with poor prognosis in idiopathic pulmonary fibrosis
por: Yamaguchi, Kakuhiro, et al.
Publicado: (2020)

Presentation of pulmonary Langerhans cell histiocytosis before the development of lung cysts
por: Martin, Irene, et al.
Publicado: (2013)

Increased Primary Cilia in Idiopathic Pulmonary Fibrosis
por: Lee, Junguee, et al.
Publicado: (2018)

Demographic and clinical profile of idiopathic pulmonary fibrosis patients in Spain: the SEPAR National Registry
por: Fernández-Fabrellas, Estrella, et al.
Publicado: (2019)

Neutrophil lymphocyte ratio as an indicator for disease progression in Idiopathic Pulmonary Fibrosis
por: Achaiah, Andrew, et al.
Publicado: (2022)

Membrane particles from mesenchymal stromal cells reduce the expression of fibrotic markers on pulmonary cells
por: Merino, Ana, et al.
Publicado: (2021)

Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation
por: Maher, Toby M., et al.
Publicado: (2019)

Functional Wnt Signaling Is Increased in Idiopathic Pulmonary Fibrosis
por: Königshoff, Melanie, et al.
Publicado: (2008)

NHLRC2 expression is increased in idiopathic pulmonary fibrosis
por: Kreus, Mervi, et al.
Publicado: (2022)

Vascular disease in COPD: Systemic and pulmonary expression of PARC (Pulmonary and Activation-Regulated Chemokine)
por: Muñoz-Esquerre, Mariana, et al.
Publicado: (2017)

Idiopathic pulmonary fibrosis
por: Meltzer, Eric B, et al.
Publicado: (2008)

Idiopathic Pulmonary Fibrosis
por: Lynch, Joseph P., et al.
Publicado: (2011)

PCSK6 and Survival in Idiopathic Pulmonary Fibrosis
por: Oldham, Justin M., et al.
Publicado: (2023)

Unmet needs in the treatment of idiopathic pulmonary fibrosis―insights from patient chart review in five European countries
por: Maher, Toby M., et al.
Publicado: (2017)

Increased FGF1-FGFRc expression in idiopathic pulmonary fibrosis
por: MacKenzie, BreAnne, et al.
Publicado: (2015)

Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events
por: Costabel, Ulrich, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_a62q3g6k1jhtb8ccvl94l9q2nc